Cart 0 Product Products (empty)
No products
To be determined Shipping
$0.00 Total
Product successfully added to your shopping cart
Quantity
Total
There are 0 items in your cart. There is 1 item in your cart.
Total products
Total shipping To be determined
Total
New Reduced price! 
View larger
View larger 
AAMI TIR48:2015
M00002606
New product
AAMI TIR48:2015 Quality Management System (QMS) Recommendations on the Application of the U.S. FDA's CGMP Final Rule on Combination Products
standard by Association for the Advancement of Medical Instrumentation, 08/14/2015
In stock
More info
Full Description
1.1 InclusionsThis Technical Information Report (TIR) provides recommendations on the application ofCGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissuebased products during development and marketing of combination products (drugdevice,biologic-device, drug-biologic, or drug-device-biologic), in accordance with theFDA's final rule (21 CFR Part 4; 78 FR 4307, 2013hereafter "The Rule" or "FDA's FinalRule"). These recommendations are intended to inform the adoption and application ofCGMPs for combination products.
1.2 Exclusions
The TIR does not address topics outside the realm of CGMPs. Additionally, the TIR mayinform practices for combination products marketed outside the United States, but it isnot intended, or considered to address non-U.S. requirements comprehensively.